Multiple Myeloma, Refractory Multiple Myeloma
Conditions
Keywords
isatuximab, wearable electronic devices, qualitative research, patient reported outcome measures
Brief summary
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable activity data will be collected. Outcomes include treatment experience, quality of life, financial toxicity, treatment adherence, symptom burden and health self-efficacy. These will be captured by patient reported outcome measures including the Patient's Qualitative Assessment of Treatment- Real World (PQAT-RW), Patient Global Impression of Change/Severity (PGIC/S), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20), and the European QoL-5 Dimensions (EQ5D), Cancer Behavior Inventory-Brief Form (CBI-B), Center for Adherence Support Evaluation (CASE) Medication Adherence Index, Comprehensive Score for Financial Toxicity (COST) Instrument. Clinical data, including treatment history, healthcare utilization, and co-morbidities, as well as demographic data will be collected via the electronic health record from each clinical site. This data will be complemented by qualitative data from a selected cohort of study participants with a focus on treatment experience ranging from infusion burden, toxicity management, to overall quality of life. Evaluation of this data in combination will be used to better understand the treatment experience of individuals on standard of care isatuximab-irfc specifically, and with relapsed or refractory multiple myeloma generally, contributing to an existing gap in the literature regarding patient reported outcomes from diverse data sources. Outcomes will be analyzed with attention to the relationship between social determinants of health, including race, ethnicity, and geographic location, and treatment experience as reflected in both the qualitative and quantitative data.
Interventions
BEHAVIORALDigital Health Coaching Program
consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
DEVICEFitbit
A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Sponsors
M.D. Anderson Cancer Center
Sanofi
University of Washington
Pack Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
A single cohort of 50 individuals with relapsed/refractory multiple myeloma will be enrolled in the study, all of which will be enrolled in a digital health coaching program and receive a Fitbit device for activity tracking. Individuals from both study sites will be enrolled to this single cohort.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 or older * Diagnosis of relapsed/refractory multiple myeloma corresponding to the Food and Drug Administration (FDA) package insert for isatuximab-irfc (Sarclisa®). * Confirmed or planned treatment with intravenous isatuximab-irfc for relapsed/refractory multiple myeloma as standard-of-care therapy. Concurrent therapy with other agents (e.g., pomalidomide) is allowed. * Access to and willingness to use a smartphone or other device through which they can send and receive text messages, emails and/or access a mobile application. * Willingness to wear and have data collected by a Fitbit * Ability to engage in physical activity as evidenced by an Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 2
Exclusion criteria
* Individuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment) * Individuals for whom there is documentation of inability to provide consent in the medical record. * Individuals receiving isatuximab-irfc subcutaneously
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW) | Change in baseline perception of treatment experience at 3 months | A 6-item survey assessing experience of a drug during clinical trial. The instrument consists of 3-free text and 3 scaled responses assessing the perceived benefits and disadvantages of received treatment and willingness to continue on drug after the study. |
| Qualitative Interview | Within the last month of study participation | A one time interview will be conducted to learn more about the experience of individuals related to their diagnosis, treatment, symptoms, side effects and overall care experience. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20) | Change in baseline perception of treatment experience at 3 months | A 20-item measure of quality of life among individuals with multiple myeloma. It assesses a series of symptoms on a 4-point Likert scale ranging from 1 (Not at All) to 4 (Very Much). |
| Change in European QoL-5 Dimensions (EQ5D) | Change in baseline perception of treatment experience at 3 months | A measure of quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
| Change in Cancer Behavior Inventory-Brief Form (CBI-B) | Change in baseline perception of treatment experience at 3 months | This 12-item instrument measures self-efficacy in coping with cancer across 7 domains. These include: Seeking and Understanding Medical Information, Emotion Regulation, Coping with Treatment Related Side Effects, Accepting Cancer/ Maintaining a Positive Attitude, Seeking Social Support, and Using Spiritual Coping. The instrument utilizes a 9-point response scale ranging from 1 Not at all confident to 9 Confident. |
| Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) | Change in baseline perception of treatment experience at 3 months | A 30-item measure of quality of life across 5 domains, including physical, emotional, social, role and cognitive), 8 symptoms, and items assessing global health and financial toxicity. Recall over the past week is scored primarily on a 4-point scale ranging from not at all to very much. The instrument may be administered either on paper or electronically. |
| Change in Patient Global Impression of Change (PGIC) Scale | Change in baseline perception of treatment experience at 3 months | A 1-item measure of patient perception of change in relapsed/refractory multiple myeloma symptoms since starting a study. Responses are scored on a 7-point scale, ranging from very much worse to very much better. |
| Change in Center for Adherence Support Evaluation (CASE) Medication Adherence Index | Change in baseline perception of treatment experience at 3 months | The Center for Adherence Support Evaluation (CASE) is a three-item questionnaire used to measure antiretroviral therapy adherence. This questionnaire was developed through the Special Projects of National Significance (SPNS) initiative called Assessing Existing Efforts to Increase Adherence to Medication. Patients take less than 5 minutes to answer the three unique questions, asking about their difficulty taking medications on time, average days per week with one dose missed, and the last time they missed a dose. |
| Change in Comprehensive Score for Financial Toxicity (COST) Instrument | Change in baseline perception of treatment experience at 3 months | The Comprehensive Score for Financial Toxicity (COST) is an 11-item instrument used to measure the financial toxicity of cancer treatment, which has been demonstrated to be highly correlated with HRQoL (de Souza et al., 2017). This instrument was validated among individuals with advanced cancer and demonstrated high internal consistency (Cronbach's α \>.90) and highly correlated to HRQol (p=.05). The instrument consists of 11 items, utilizing a five-point ordinal scale ranging from (0- Not at all) to (4- Very much). |
| Change in Patient Global Impression of Severity (PGIS) Scale | Change in baseline perception of treatment experience at 3 months | A 1-item measure of severity of relapsed/refractory multiple myeloma symptoms since the last visit, which is scored a on a 5-response scale ranging from none to very severe. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Physical Activity | From date of enrollment up to 3 months | Physical activity, including step count and minutes of physical activity will be collected via Fitbits provided to study participants |
| Digital Engagement | From date of enrollment up to 3 months | Frequency, types and duration of engagement with the digital health coaching platform |
| Health Care Utilization | From date of enrollment up to 3 months | ER visits and unplanned hospitalizations |
Countries
United States
Contacts
Primary ContactKelly J Brassil, PhD
Backup ContactJennifer Loftis, DNP
Outcome results
None listed